Literature DB >> 21617886

The Third Consensus Conference on the treatment of aplastic anemia.

Seiji Kojima1, Shinji Nakao2, Neal Young2, Andrea Bacigalupo2, Gerard Gerard2, Naoto Hirano2, Jaroslaw Maciejewski2, Joachim Deeg2, Judith Marsh2, Feng-Kui Zhang2, Jong Wook Lee2, Keiya Ozawa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21617886     DOI： 10.1007/s12185-011-0873-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  37 in total

1.  Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

Authors:  A Bacigalupo; F Locatelli; E Lanino; J Marsh; G Socié; S Maury; A Prete; A Locasciulli; S Cesaro; J Passweg
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

2.  Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.

Authors:  H Joachim Deeg; Margaret O'Donnell; Jakub Tolar; Rajni Agarwal; Richard E Harris; Stephen A Feig; Mary C Territo; Robert H Collins; Peter A McSweeney; Edward A Copelan; Shakila P Khan; Ann Woolfrey; Barry Storer
Journal:  Blood       Date:  2006-05-09       Impact factor: 22.113

3.  Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Authors:  E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

4.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.

Authors:  Chiharu Sugimori; Tatsuya Chuhjo; Xingmin Feng; Hirohito Yamazaki; Akiyoshi Takami; Masanao Teramura; Hideaki Mizoguchi; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

5.  Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.

Authors:  F Locatelli; B Bruno; M Zecca; M T Van-Lint; S McCann; W Arcese; S Dallorso; P Di Bartolomeo; F Fagioli; A Locasciulli; M Lawler; A Bacigalupo
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

6.  Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

Authors:  Seiji Kojima; Takaharu Matsuyama; Shunichi Kato; Hisato Kigasawa; Ryoji Kobayashi; Atsushi Kikuta; Hisashi Sakamaki; Koichiro Ikuta; Masahiro Tsuchida; Yasutaka Hoshi; Yasuo Morishima; Yoshihisa Kodera
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

7.  Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia.

Authors:  Nao Yoshida; Hiroshi Yagasaki; Yoshiyuki Takahashi; Tomoko Yamamoto; Juan Liang; Yue Wang; Makito Tanaka; Asahito Hama; Nobuhiro Nishio; Ryoji Kobayashi; Noriko Hotta; Keiko Asami; Atsushi Kikuta; Takashi Fukushima; Naoto Hirano; Seiji Kojima
Journal:  Br J Haematol       Date:  2008-06-03       Impact factor: 6.998

8.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.

Authors:  Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

9.  Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.

Authors:  Hiroshi Yagasaki; Seiji Kojima; Hiromasa Yabe; Koji Kato; Hisato Kigasawa; Hisashi Sakamaki; Masahiro Tsuchida; Shunichi Kato; Takakaza Kawase; Hideki Muramatsu; Yasuo Morishima; Yoshihisa Kodera
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-04       Impact factor: 5.742

10.  Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan.

Authors:  Masanao Teramura; Akiro Kimura; Satsuki Iwase; Yuji Yonemura; Shinji Nakao; Akio Urabe; Mitsuhiro Omine; Hideaki Mizoguchi
Journal:  Blood       Date:  2007-05-25       Impact factor: 22.113
View more
  9 in total

1.  Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia.

Authors:  Tatsuhiro Sakamoto; Naoshi Obara; Naoki Kurita; Mamiko Sakata-Yanagimoto; Hidekazu Nishikii; Yasuhisa Yokoyama; Kazumi Suzukawa; Yuichi Hasegawa; Shigeru Chiba
Journal:  Int J Hematol       Date:  2013-08-21       Impact factor: 2.490

2.  Single nucleotide polymorphism array analysis of bone marrow failure patients reveals characteristic patterns of genetic changes.

Authors:  Daria V Babushok; Hongbo M Xie; Jacquelyn J Roth; Nieves Perdigones; Timothy S Olson; Joshua D Cockroft; Xiaowu Gai; Juan C Perin; Yimei Li; Michele E Paessler; Hakon Hakonarson; Gregory M Podsakoff; Philip J Mason; Jaclyn A Biegel; Monica Bessler
Journal:  Br J Haematol       Date:  2013-10-14       Impact factor: 6.998

3.  Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations.

Authors:  Takahiro Suzuki; Hiroyuki Kobayashi; Yasufumi Kawasaki; Kiyoshi Okazuka; Kaoru Hatano; Shin-Ichiro Fujiwara; Iekuni Oh; Ken Ohmine; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2016-06-23       Impact factor: 2.490

4.  Expression of IL-27, Th1 and Th17 in patients with aplastic anemia.

Authors:  Hui-zhen Du; Qian Wang; Jian Ji; Bao-ming Shen; Shao-chun Wei; Li-juan Liu; Juan Ding; Dao-xin Ma; Wen Wang; Jun Peng; Ming Hou
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

5.  Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria.

Authors:  Régis Peffault de Latour; Hubert Schrezenmeier; Andrea Bacigalupo; Didier Blaise; Carmino A de Souza; Stephane Vigouroux; Roelf Willemze; Louis Terriou; Andre Tichelli; Mohamad Mohty; Sophie de Guibert; Judith C Marsh; Jakob Passweg; Jean Yves Mary; Gerard Socié
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 6.  Acquired aplastic anemia in children.

Authors:  Helge D Hartung; Timothy S Olson; Monica Bessler
Journal:  Pediatr Clin North Am       Date:  2013-10-16       Impact factor: 3.278

7.  Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation.

Authors:  Beatrice Drexler; Felicitas Zurbriggen; Tamara Diesch; Romaine Viollier; Joerg P Halter; Dominik Heim; Andreas Holbro; Laura Infanti; Andreas Buser; Sabine Gerull; Michael Medinger; André Tichelli; Jakob R Passweg
Journal:  Ann Hematol       Date:  2020-09-19       Impact factor: 3.673

Review 8.  Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: a Cochrane systematic review.

Authors:  Frank Peinemann; Alexander Michael Labeit
Journal:  BMJ Open       Date:  2014-07-15       Impact factor: 2.692

9.  Allogeneic hematopoietic stem cell transplantation as the first-line treatment option in a patient with severe aplastic anemia without a matched related donor: A case report.

Authors:  Shun-Neng Hsu; Jia-Hong Chen; Woei-Yau Kao
Journal:  Oncol Lett       Date:  2014-07-10       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.